⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MIST News
Milestone Pharmaceuticals Inc. Common Shares
Form 8-K
sec.gov
MIST
Milestone Pharmaceuticals Announces NMPA Approval of Etripamil Nasal Spray for PSVT in China, Marking First Regulatory Approval of Etripamil Outside of the United States
globenewswire.com
MIST
Milestone Pharmaceuticals to Present at Upcoming Investor Conferences
globenewswire.com
MIST
Milestone Pharmaceuticals Announces Data Presented at ESC Congress 2026 on the Impact of Paroxysmal Supraventricular Tachycardia (PSVT) on Patients’ Daily Lives and Quality of Life Between Episodes
globenewswire.com
MIST
Milestone Pharmaceuticals Initiates Pivotal Phase 3 Trial of Etripamil Nasal Spray for Self-Administered Treatment of Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR)
globenewswire.com
MIST
Form 8-K
sec.gov
MIST
Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com
MIST
Global Ultrasonic Testing Market Report Now Available — Examines Oil and Gas, Manufacturing, Aerospace, Power Generation, and Automotive End Uses
globenewswire.com
BKR
MIST
Tiny Reports Q2 2026 Results Ready to Announce with Confidence?
newsfilecorp.com
MSFT
XOM
NVDA
GOOG
AMZN
META
TSLA
SPCE
QTRX
MIST
Milestone Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 12, 2026
globenewswire.com
MIST